The global theranostics market was valued at USD 2.42 billion in 2024, grew to USD 2.8 billion in 2025, and is projected to reach USD 10.21 billion by 2034, expanding at a CAGR of 15.46% (2025–2034). North America accounted for 40% of revenue in 2024, while Asia Pacific is anticipated to witness the fastest growth. The market is fueled by rising cancer prevalence, growth in radiopharmaceuticals, molecular imaging advancements, and the integration of AI in personalized medicine. By product, radiopharmaceuticals (38% share, 2024) dominated, while immunotherapeutics are expected to grow fastest. By technology, molecular imaging (32% share, 2024) led, with nanoparticle-based theranostics expected to expand rapidly.
Download the free sample and get the complete insights and forecasts report on this market @ https://www.towardshealthcare.com/download-sample/6009
◉2024 → USD 2.42 Billion (baseline market value).
◉2025 → USD 2.8 Billion (early expansion, fueled by PET/SPECT adoption).
◉2034 (Projection) → USD 10.21 Billion.
◉(2025–2034) → CAGR 15.46%, among the fastest in precision oncology markets.
◉North America → 40% share, advanced healthcare + nuclear medicine infrastructure.
◉Asia Pacific → fastest growth forecast (oncology adoption, new radiopharmaceuticals).
◉Europe → driven by supportive policies, R&D, biotech collaborations.
◉Oncology-Centric Growth → Prostate and neuroendocrine cancers dominate adoption, with PSMA-based tracers and Lu-177 DOTATATE therapy.
◉Shift to Non-Oncology Applications → Expansion into neurology, cardiology, and infectious diseases (e.g., radiopharmaceuticals for brain disorders).
◉AI in Imaging → AI integration in PET/SPECT and radiomics is enabling more precise tumor mapping.
◉Nanoparticle-Based Therapies → Use of liposomes, polymeric nanoparticles, and gold nanoparticles to enhance targeted drug delivery.
◉Growing Radiopharmaceutical Investments → Partnerships like NorthStar + YAP (2025) and Curium +
◉PDRadiopharma (2024) expanding clinical use.
◉Collaborative Ecosystem → Industry-academic collaborations (Siemens Healthineers + MGH, 2025) accelerating adoption.
◉Personalized Medicine Push → Increased demand for companion diagnostics supporting therapy selection.
◉AI-driven Trial Accessibility → SNMMI’s AI-based Global Radiopharmaceutical Trial Finder (2025) enhancing patient-trial matching.
◉Infrastructure Barriers → High expenditure for PET/SPECT systems and isotope production facilities restrains widespread adoption.
◉Enables quantitative tumor analysis from PET/SPECT/CT scans.
◉Helps detect heterogeneity in tumors → better selection of targeted therapy.
◉Optimizes radiation dose planning → minimizes exposure to healthy tissues.
◉Example: AI-based anatomical + tumor property analysis improving radiation safety.
◉SNMMI’s Global Radiopharmaceutical Trial Finder (2025) → AI-driven platform matching patients with theranostic clinical trials globally.
◉Predicts treatment response curves for individual patients.
◉Integration with biomarkers → precision dosing recommendations.
◉Helps in identifying new molecular targets (e.g., HER2, FAP).
◉Speeds up preclinical testing by simulating molecular interactions.
◉Diagnostic imaging centers adopting AI for automated scan analysis → faster and cheaper than manual radiologist evaluations.
◉Cancer prevalence (prostate, NETs) driving PSMA-targeted radiopharmaceuticals.
◉Robust regulatory & reimbursement framework supporting adoption.
◉Key collaboration (Jan 2025) → NorthStar Medical Radioisotopes + YAP Therapeutics to develop novel radiopharmaceuticals.
◉China: Government’s Medical Isotopes Development Plan (2021–2035) expanding nuclear medicine capacity.
◉Japan: Investments in PET/CT imaging + theranostic radiotracers; collaboration with Curium for PSMA-based therapies.
◉India & South Korea: Expanding PET/SPECT infrastructure, rising cancer burden.
◉Germany: Strong biotech ecosystem; Nuclidium raised CHF 79M (2025) for copper-based radiopharma pipeline.
◉UK: Growing awareness, partnerships (Lemer Pax + Synapse Medical, 2025) to expand radiation protection systems.
◉France, Italy, Spain → National nuclear medicine programs fueling adoption.
◉Brazil: ICPO + SBMN partnership (2025) to establish Clinical Theranostics Centers.
◉Growing use of PET/SPECT but limited isotope production infrastructure.
◉Saudi Arabia, UAE → rapid investments in advanced imaging infrastructure.
◉South Africa → limited adoption but growing nuclear medicine R&D centers.
◉Products: PET/CT, SPECT/CT, CT systems, radiopharmacy automation.
◉Overview: Leader in diagnostic hardware & imaging workflow software; broad clinical installed base.
◉Strength: Global distribution, upgrade pipelines, strong clinical evidence and service footprint enabling hospital adoption.
◉Products: PET, PET/CT, advanced imaging analytics, AI-enabled imaging suites; therapy informatics via research collaborations.
◉Overview: Heavy investment in imaging + digital platforms; active research partnerships (e.g., MGH Therapy Command Center).
◉Strength: Deep clinical partnerships, end-to-end imaging solutions and growing therapy orchestration capabilities.
◉Products: Radiochemistry consumables, lab analyzers, clinical diagnostics, radiopharma manufacturing tools.
◉Overview: Strong in upstream lab and manufacturing supply for radiopharma development.
◉Strength: Global CDMO-like capabilities, regulatory and quality expertise for cGMP radiochemistry.
◉Products: PSMA and other prostate cancer imaging/therapeutic radiopharmaceuticals (Gozellix launch).
◉Overview: Focused oncology theranostics player with diagnostic and therapeutic pipeline.
◉Strength: Clinical focus, regulatory progress in targeted prostate imaging and therapy markets.
◉Products: Broad nuclear medicine portfolio, including Lu-177 products and isotope manufacturing.
◉Overview: Large nuclear medicine player with manufacturing reach in APAC and Europe.
◉Strength: Radiopharma manufacturing scale, regulatory filings and commercial partnerships (e.g., Japan collaborations).
◉Overview: Mix of isotope producers (NorthStar), imaging/contrast firms (Bracco), big-pharma R&D (Novartis/Bayer) now entering theranostics through acquisitions, licensing and internal pipelines.
◉Strengths: Vertical integration potential (drug + diagnostic + supply), brand/regulatory capital, and payer relationships.
◉Rising cancer prevalence (US, China, India, Japan) and demand for personalized oncology drive adoption of imaging + targeted therapy pairs.
◉Molecular imaging advances (new PET tracers, FAPI, PSMA), nanoparticle formulations, and AI analytics accelerate diagnostic sensitivity and therapy selection.
◉CDMO expansion, oncology trial activity, and increasing hospital-level theranostics programs (centers of excellence) lower commercialization barriers.
◉High upfront costs for scanners, cyclotrons/generators and shielded radiopharmacies; training and staffing shortages.
◉Short isotope half-lives require local/regional production; limited global reactor/cyclotron capacity constrains scale (logistics and shelf-life issues).
◉Novel agents combine drug and radioactive material regulations; inconsistent guidance across regions slows global launches.
◉Neurology, cardiology, and infectious disease theranostics present new addressable markets beyond oncology.
◉AI-driven dosimetry and outcome prediction can increase therapeutic efficacy and improve payer acceptance through better value demonstration.
◉New molecular targets (HER2, FAP, CXCR4) and biomarker-guided patient selection increase therapy success rates.
◉Regulators historically have limited experience with radiotheranostics relative to conventional oncology drugs; sponsors face uncertainty on data expectations and global alignment. This variability increases development complexity and cost.
◉EMA maintains specific scientific guidance for radiopharmaceuticals and has been revising guidance to harmonize early-phase trial expectations, dosimetry and combination regimens — such guideline modernization is intended to reduce ambiguity but requires sponsors to adapt submissions and dosimetry standards.
◉FDA initiatives (e.g., oncology early guidance like OREEG) provide educational/regulatory support for early developers in oncology and can shorten development timelines if leveraged; however, theranostic filings still face specialized review pathways for radioactive products.
◉Increased clarity → faster translation: Cleared guidance on dosimetry and early-phase expectations encourages investment and trial design standardization.
◉Safety & dosimetry emphasis: Regulators are requiring more robust dosimetry and radiation safety data (human biodistribution, organ doses), raising trial complexity and costs.
◉Harmonization challenges: Divergent regional expectations (CMC, release testing, radiolabelling standards) force sponsors to create region-specific packages or run duplicative supporting studies, slowing global rollouts.
◉Short term: slower approvals for novel agents where guidance is still evolving; increased sponsor costs.
◉Medium/long term: as guidance harmonizes and reviewers gain experience, regulatory clarity will decrease risk and increase investment, accelerating the market (consistent with the projected CAGR).
Governments (national health systems, research funds) that fund local isotope production (reactors, cyclotrons, generator programs) reduce logistical barriers to theranostics and enable same-day delivery models required by short-half-life agents. The Australian discussion (calls for a Nuclear Medicine Fund) exemplifies this need for national investment to scale access.
Reimbursement for companion diagnostics + therapy pairs is pivotal: where payers provide bundled coverage for diagnostic testing and subsequent therapy, adoption is far faster. Conversely, fragmented reimbursement (diagnostic reimbursed but therapy not, or vice versa) dampens uptake and discourages clinical program development.
◉Regulatory programs (e.g., FDA’s expedited programs, early regulatory guidance platforms) reduce clinical development risk and attract capital for high-need theranostic agents.
◉Countries are incorporating theranostics into national cancer planning (e.g., China’s mid/long-term development plan for medical isotopes); such strategic inclusion directs public funds toward facility buildout and clinical trials.
◉Public investment in manufacturing and distribution infrastructure (generators, cyclotrons, CDMOs) reduces unit cost and geographic disparities in access — essential for therapies requiring short-lived isotopes.
◉Governments that fund clinical trial networks and registries (or build AI trial-matching tools) accelerate patient recruitment and evidence generation, improving payer confidence.
◉Supply chain challenges (isotope production capacity, logistics) are both a technical and a policy problem; regulatory modernization without parallel investment in manufacturing will leave access gaps. Reviews and expert commentaries emphasize the need for both guidance and manufacturing scale-up to realize theranostics’ potential.
◉Philochem AG → RayzeBio: Transfer commercialization & manufacturing responsibilities for OncoACP3, a prostate targeting theranostic — signals consolidation and larger commercial pathways for promising candidates.
◉Siemens Healthineers ↔ MGH: Research partnership for a Therapy Command Center — a model for integrating imaging, AI analytics and therapeutic orchestration across clinical teams.
TAG1 → PharmaLogic (partnership): To broaden Pb-212 generator access (improves alpha-therapy supply chain).
◉Champions Oncology: Launched a radiopharmaceutical services platform — evidence of increasing outsourced demand for radiopharma services (trial support, radiochemistry).
◉Telix: U.S. launch of Gozellix (prostate imaging) — expands PSMA imaging availability and supports therapy triage.
◉GE Healthcare: New cardiac CT improves cross-specialty diagnostic integration relevant to theranostics applications in cardiology.
Commercial launches & platform expansion: Telix launched Gozellix (prostate imaging) in the U.S. (June 2025) — increases diagnostic access for PSMA imaging and feeds therapeutic decisioning.
Service offerings & CDMO growth: Champions Oncology launched a radiopharmaceutical services platform (July 2025), reflecting greater demand for contract R&D and manufacturing capacity.
Imaging hardware enhancements: GE Healthcare introduced CT innovations (Unlimited One-Beat Cardiac) improving cardiac imaging — relevant where theranostics intersects cardiology (April 2025).
Strategic partnerships for development/commercial scale: Philochem → RayzeBio deal (June 2025) for OncoACP3, Siemens Healthineers ↔ MGH Therapy Command Center (June 2025), NorthStar ↔ YAP (Jan 2025) for isotope & radiopharma partnerships — showing cross-sector cooperation needed to scale theranostics.
◉Increased CDMO / generator investments and specific Pb-212 and Lu-177 initiatives indicate industry response to isotope supply bottlenecks and alpha-therapy demand.
◉Radiopharmaceuticals were the largest product type in 2024 (38% share) and form the backbone of theranostics by combining a targeting ligand with a radioactive payload for both imaging and therapy.
◉Subclasses: beta emitters (e.g., Lu-177), alpha emitters (e.g., Pb-212, Ac-225), and Auger emitters — each with distinct therapeutic ranges, dosimetry profiles, and manufacturing/supply constraints.
◉Clinical use: companion imaging tracers (PET/SPECT) for patient selection followed by therapeutic isotopes targeted to the same biomarker (classic “pair” model).
◉High R&D and cGMP radiochemistry costs; dependence on isotope supply chains (generators, cyclotrons, reactors).
◉Regulatory and reimbursement complexity (drug + device + radioactive material handling) increases time-to-market and commercial risk.
◉Molecular imaging (32% share in 2024) — PET leads within this segment due to whole-body quantitative imaging and established tracer pipelines (e.g., PSMA, FDG analogues).
◉Hybrid modalities (PET/CT, PET/MRI) enable precise localization and dosimetry planning for therapeutic delivery.
◉MRI contrast agents, optical/ultrasound agents and SPECT tracers still play important roles in multi-modal theranostic workflows (staging, response assessment).
◉Liposomes, polymeric nanoparticles, gold nanoparticles: used to carry both imaging moieties and therapeutic payloads or to modify pharmacokinetics (targeting, BBB penetration).
◉Offer controlled release, multifunctionality (targeting + imaging + therapy), and potential to expand beyond classical radiotheranostics into chemo/radio combinations.
◉Nanomaterials demand additional characterization (size, surface chemistry), safety testing (biodistribution, clearance) and raise novel CMC/regulatory questions relative to small molecules and proteins.
◉PET/SPECT scanners, cyclotrons, isotope generators and therapy delivery systems (shielded infusion systems, radiopharmacy automation) are critical capital items.
◉Hospitals & clinics account for the largest end-user revenue (45% in 2024) because they consolidate imaging, therapy and inpatient care.
The market is segmented into blood glucose monitoring devices (continuous glucose monitors, self-monitoring kits, lancets, test strips) and insulin delivery devices (insulin pumps, smart pens, syringes). Supporting software, apps, and AI-driven digital platforms form an emerging sub-segment.
Major players include Medtronic, Abbott Laboratories, Dexcom, F. Hoffmann-La Roche, Insulet Corporation, Tandem Diabetes Care, Novo Nordisk, and Eli Lilly. These firms lead innovation in CGM, insulin pump therapy, and AI-powered diabetes management.
March 2025: Tandem Diabetes Care launched Control-IQ+ tech for type 1 & type 2 diabetics in the U.S., enhancing personalization.
February 2025: FDA approved Tandem’s Control-IQ+ for type 2 diabetes.
January 2025: Dexcom advanced next-gen CGM sensors with improved wearability and integration.
These developments highlight regulatory approvals and innovation in closed-loop systems.
Regulatory bodies like the FDA, EMA, and CDSCO are fast-tracking approvals for digital health and AI-driven diabetes solutions. Stricter data security, interoperability standards, and device safety requirements are reshaping product development, while reimbursement frameworks are expanding to cover CGM and insulin pump use in type 2 diabetes patients.
Access our exclusive, data-rich dashboard dedicated to the diagnostics sector– built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/6009
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
The global nootropics market size reached USD 5.71 billion in 2025 and is projected to grow to USD 19.53 billion… Read More
The U.S. concierge medicine market was valued at USD 7.25 billion in 2024, grew to USD 8 billion in 2025,… Read More
The global recombinant proteins market is valued at USD 3.36 billion in 2025 and projected to reach USD 8.08 billion… Read More
The global digital biomarkers market was valued at USD 5.09 billion in 2025 and is projected to reach USD 32.37… Read More
The global chemotherapy market is estimated at USD 10.28 billion in 2025 and projected to reach USD 19.35 billion by… Read More
The global endoscopy devices market was valued at USD 61.1 billion in 2024, increased to USD 63.44 billion in 2025,… Read More